{"filing":{"accession_number":"0001213900-26-099524","cik":"0001782107","ticker":"ONCO","company_name":"Onconetix, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-11","primary_document":"ea0305157-8k_onconetix.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026099524/ea0305157-8k_onconetix.htm"},"events":[{"id":33206,"run_id":30527,"accession_number":"0001213900-26-099524","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.89,"summary":"Onconetix entered into a Grid Promissory Note with Realbotix LLC providing up to $5.0 million in bridge financing to support the pending acquisition of Realbotix announced in February 2026. The bridge facility is automatically cancelled and discharged upon closing of the Share Exchange Agreement, reducing cash required at closing.","company_name":"Onconetix, Inc.","ticker":"ONCO","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36585,"accession_number":"0001213900-26-099524","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Item 1.01 disclosure centers on Onconetix entering into a Grid Promissory Note with Realbotix LLC to provide bridge financing of up to $5.0 million in support of a pending acquisition. While the Note itself is the immediate subject, the filing explicitly frames this as \"strategic bridge financing...in support of [the] pending acquisition\" and notes that the Note will be \"automatically cancelled and discharged in full\" upon closing of the Share Exchange Agreement announced February 11, 2026. The bridge financing is materially connected to and contingent upon the acquisition transaction, making this disclosure fundamentally about M\u0026A activity—specifically, entry into a material definitive agreement that facilitates the acquisition of Realbotix by Onconetix.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T14:39:45.877145+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36586,"accession_number":"0001213900-26-099524","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a strategic bridge financing facility of up to $5 million provided by Onconetix to Realbotix LLC, the target of a previously announced pending acquisition under a Share Exchange Agreement. While Item 7.01 is a Regulation FD disclosure, the substance centers on financing activity directly supporting the pending acquisition announced February 12, 2026. The press release emphasizes that the facility is \"automatically cancelled and discharged in full upon closing\" and reduces cash required at closing, making it integral to the M\u0026A transaction structure. This is material to investors assessing the acquisition's progress and financing terms.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T14:39:45.877145+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36585,"accession_number":"0001213900-26-099524","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The Item 1.01 disclosure centers on Onconetix entering into a Grid Promissory Note with Realbotix LLC to provide bridge financing of up to $5.0 million in support of a pending acquisition. While the Note itself is the immediate subject, the filing explicitly frames this as \"strategic bridge financing...in support of [the] pending acquisition\" and notes that the Note will be \"automatically cancelled and discharged in full\" upon closing of the Share Exchange Agreement announced February 11, 2026. The bridge financing is materially connected to and contingent upon the acquisition transaction, making this disclosure fundamentally about M\u0026A activity—specifically, entry into a material definitive agreement that facilitates the acquisition of Realbotix by Onconetix.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T14:39:45.877145+00:00","company_name":"Onconetix, Inc.","ticker":"ONCO","filing_date":"2026-09-14"},{"id":36586,"accession_number":"0001213900-26-099524","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a strategic bridge financing facility of up to $5 million provided by Onconetix to Realbotix LLC, the target of a previously announced pending acquisition under a Share Exchange Agreement. While Item 7.01 is a Regulation FD disclosure, the substance centers on financing activity directly supporting the pending acquisition announced February 12, 2026. The press release emphasizes that the facility is \"automatically cancelled and discharged in full upon closing\" and reduces cash required at closing, making it integral to the M\u0026A transaction structure. This is material to investors assessing the acquisition's progress and financing terms.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T14:39:45.877145+00:00","company_name":"Onconetix, Inc.","ticker":"ONCO","filing_date":"2026-09-14"}]}